₹120 to ₹238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?
Over the last 22 trading sessions, Suven Life Sciences has surged from ₹ 120 to ₹ 238 apiece, marking a sharp rise of 98.3%. The stock ended May with an impressive 92% monthly gain — its best performance since December 2020, when it had rallied 95%.
Several factors have contributed to this sharp uptrend, with one of the key drivers being the company's recently raised ₹ 857 crore through a preferential issue. In mid-May, the company's board approved the issue of 6.4 crore fully convertible warrants on a preferential basis to promoters and non-promoter entities, each priced at ₹ 134.
The funds raised will support various initiatives, including ongoing R&D efforts, clinical trials, general corporate purposes, and the development of a new research facility focused on CNS (central nervous system) therapies.
Additionally, investor sentiment remains positive due to the company's strong clinical pipeline. Suven Life Sciences is currently advancing multiple CNS-focused drug candidates through various stages of clinical trials—Phases 1, 2, and 3—for conditions such as Alzheimer's disease, narcolepsy, major depressive disorder, and cognitive impairment.
Despite the company's posting widening losses in the March quarter, investors remain optimistic about the company's long-term growth prospects. The company's emphasis on developing novel therapeutics for neurodegenerative disorders and CNS diseases, backed by the new fundraising, reinforces its potential for long-term growth, attracting investor interest.
For the March-ending quarter, the company reported a widening of consolidated net loss to ₹ 43.95 crore from ₹ 27 crore in Q4FY24, hit by a dip in revenue and higher expenses. Its consolidated revenue from operations in the quarter under review stood at ₹ 1.47 crore against ₹ 2.39 crore in the year-ago period, it added.
Total expenses in the March quarter were higher at ₹ 46.63 crore as compared to ₹ 34.21 crore in the same period a year ago. In fiscal year 2024-25, consolidated net loss widened to ₹ 160.75 crore from ₹ 105.08 crore in the previous fiscal year, while the consolidated revenue from operations in FY25 stood at ₹ 6.66 crore as compared to ₹ 11.69 crore in FY24, the company said.
The company, in its earnings filing, said that it continues the R&D programs focused on central nervous system (CNS) disease disorders and granted 20 patents during the period covering the countries of Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa, and the USA.
Suven, a biopharmaceutical company, is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs globally.
The company has a portfolio of advanced-stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), schizophrenia, pain disorders, and gastrointestinal disorders.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
How technology can help ease dementia diagnosis and care burden in India
Dementia is a growing problem, particularly in a country like India, which has a rapidly ageing population. Awareness, diagnosis and access to care however, continue to remain limited. Can digital and assistive technologies help? Researchers and doctors say there is a lot of potential, but the challenge is, in making them affordable for patients. The burden According to the World Health Organization (WHO), over 55 million people worldwide live with dementia, with nearly 10 million new cases added annually. Alzheimer's disease is the most common form, contributing to 60–70% of cases. Low- and middle-income countries, including India, bear the greatest burden, with dementia prevalence expected to triple by 2050 due to demographic ageing. Emerging technologies 'In India, assistive and digital technologies are emerging as force multipliers,' said Prabash Prabhakaran, director and senior consultant, neurology, SIMS Hospital, Chennai. These range from GPS trackers and low-cost Internet of Things (IoT) wearables for patients who wander or leave their designated areas, to home sensors that monitor movement, appliance usage, or medication adherence. Smartwatches and wearable devices for activity, sleep and fall detection are becoming more common, while smartphone-based cognitive screening apps and gamified brain-training tools are in validation stages. Virtual reality modules are also being piloted, designed in vernacular languages and Indian cultural settings for reminiscence therapy and navigation training. At the research frontier, Indian centres are developing blood-based biomarker panels for early Alzheimer's detection, alongside AI-driven multimodal digital biomarkers that combine gait, speech, typing patterns and passive smartphone signals. 'Earlier and scalable detection is becoming possible because smartphone penetration is high, even among older households,' Dr. Prabhakaran explained. Studies have shown that keystroke dynamics, speech analysis and passive phone use can serve as unobtrusive early-warning signals. Sindhuja L., consultant neurophysician at V.S. Hospitals, Chennai, said AI now picks up subtle changes 'in brain scans, speech or even handwriting that escape the human eye.' She noted that digital biomarkers such as walking speed and reaction time are being captured on tablets and smartphones, even by mobile health units visiting rural communities. Dr. Prabhakaran stressed that these technologies are not replacements for clinical diagnosis, but 'powerful early detection and monitoring tools, especially valuable in India where clinic-based testing is episodic.' Easing caregiver stress 'Dementia disrupts daily living, independence, and safety while burdening caregivers. Assistive technologies help maintain independence and reduce stress,' Dr. Prabhakaran said. In practice, families are using GPS trackers, pill-box alarms, fall detectors, and voice-assisted reminders. Smart-home solutions, such as motion-triggered lights and automatic stove shut-offs, are now feasible in urban settings. Therapeutic tools also show promise. Virtual reality reminiscence therapy has allowed patients to revisit festivals or familiar neighbourhoods, sparking positive memories. 'When families join in brain-training games in local languages, they turn into a shared, engaging activity instead of a medical routine,' Dr. Sindhuja said. Gaps and digital-first solutions Nearly two-thirds of India's older adults live in rural areas, where dementia specialists are scarce. 'Travel distance, cost, stigma, and shortage of trained specialists mean many cases remain undiagnosed or untreated,' Dr. Prabhakaran said. Here, telemedicine, remote monitoring, and community-driven digital platforms offer a bridge. Accredited frontline health workers can use smartphone screening apps, while caregivers rely on WhatsApp-based peer groups for emotional and practical support. Dr. Sindhuja emphasised that 'scheduled video calls or remote monitoring can catch problems before they escalate, making care less isolating.' High costs, lack of insurance, and uneven after-sales support remain critical hurdles. 'Most advanced devices are imported and unaffordable for average families,' said Dr. Sindhuja. In rural areas, poor connectivity worsens access. Cultural barriers also persist, as memory loss is still seen as part of normal ageing, leading to delayed care-seeking. Considering these challenges, Sridhar Vaitheeswaran, consultant psychiatrist and the head of DEMCARES (Dementia Care in SCARF) at the Schizophrenia Research Foundation (SCARF) in Chennai, said the Foundation, in collaboration with Imperial College London, has been working on technologies like the humanoid robot to assist people living with dementia, offering companionship and cognitive support. SCARF is also developing virtual reality services and using platforms such as Zoom to help patients connect with their families. The aim is to improve these tools and create more seamless ways for people with dementia to stay engaged and supported. Need for subsidies Dr. Prabhakaran called for policy interventions including subsidies, insurance inclusion, and local-language adaptation. He proposed 'digital dementia corners' at primary health centres, equipped with tablets, VR stations, and screening kiosks. Doctors emphasised the need for public–private partnerships to localise production, ensure affordability, and drive awareness campaigns in regional languages. Towards a national dementia-tech ecosystem A wide range of assistive technologies is used globally-- In Japan, scannable QR codes and wearable barcodes are widely used to help locate individuals who wander. The U.K. promotes the use of reminder clocks, smart home sensors and medication dispensers through the National Health Services and dementia charities. In the U.S., devices like AngelSense integrate GPS tracking, two-way communication and fall detection, offering comprehensive monitoring. Australia supports telecare systems and simplified tablets for memory and social engagement. Sweden and the Netherlands are pioneers in using smart homes and robotic companions for dementia care, incorporating AI and ambient monitoring. These innovations, however, remain out of reach for most Indian families. The challenge, experts argue, is not just scientific but systemic, ensuring that validated, affordable, culturally relevant technologies reach homes across India. The path forward lies in scalable, inclusive technology, integrated with grassroots healthcare and caregiver networks. As Dr. Prabhakaran explained, 'Assistive devices, GPS trackers, smart-home solutions, and therapeutic tools are not luxuries: they are critical enablers of safer, more independent living. With proper validation, affordability, and integration into national elder-care programmes, these technologies can transform dementia care in the coming decade.'
Time of India
5 hours ago
- Time of India
India's banking giant launches investment funds in UAE: Check the details here!
Kotak Mahindra becomes the first Indian entity to obtain a UAE SCA license/Image: File Kotak Mahindra Bank, one of India's leading banking and financial groups, has taken a major step in its global expansion by receiving a license from the UAE Securities & Commodities Authority (SCA). This makes Kotak Mahindra (International) Ltd. the first Indian institution officially authorized to offer investment fund and portfolio management operations in the United Arab Emirates. TL;DR: Kotak Mahindra becomes the first Indian entity to obtain a UAE SCA license for portfolio and investment fund management. The bank will launch UAE-domiciled investment funds, primarily offering India-focused investment options to local and regional investors. Kotak plans to open subscriptions in the UAE by the last quarter of 2025, marking a milestone in India-UAE financial ties post-CEPA. Details of the UAE launch Kotak Mahindra (International) Ltd. (KMIL), a subsidiary of Kotak Mahindra Bank, is now fully licensed to provide a range of portfolio management and investment fund services in the Emirates. The new license paves the way for the launch of UAE-domiciled funds targeting retail investors, with subscription expected to be available from Q4 2025. Kotak will focus on offering India-centric investment strategies, allowing UAE investors to better diversify their portfolios through both Luxembourg-domiciled (UCITS) and India-based products. This move follows a surge in cross-border business and investments between India and the UAE, especially after the Comprehensive Economic Partnership Agreement (CEPA). Market watchers see Kotak's entry as a sign of deepening financial integration and new opportunities for wealth management in the region. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Use an AI Writing Tool That Actually Understands Your Voice Grammarly Install Now Undo About Kotak Mahindra Bank Kotak Mahindra Bank is among India's largest and most diversified financial service companies. Founded in 1985 as Kotak Capital Management Finance Ltd., the firm became a fully-fledged commercial bank in 2003 after receiving a banking license from the Reserve Bank of India. The group offers a wide spectrum of services, retail and corporate banking, asset management, investment banking, life insurance, and wealth management. Kotak Mahindra Bank is listed on India's major stock exchanges and is widely recognized for its strong performance, innovation, and commitment to sound risk management. Its international presence is steadily growing, especially in the Middle East. Kotak Mahindra's entry into the UAE as the first licensed Indian investment fund manager is set to increase India-focused investment choices for UAE clients and enhance financial linkages between the two major economies. Subscriptions to new Kotak funds are anticipated to open in late 2025, broadening the investment landscape for retail clients in the Emirates. FAQ 1. What is the recent milestone achieved by Kotak Mahindra in the UAE? Kotak Mahindra (International) Ltd. became the first Indian entity to receive a UAE SCA license for investment fund and portfolio management. 2. What services will Kotak Mahindra offer in the UAE? The bank will launch UAE-domiciled investment funds, focusing on India-centric portfolios for retail investors. 3. When can UAE investors subscribe to Kotak Mahindra's new funds? Subscriptions are expected to open by the last quarter of 2025. 4. How does this move affect India-UAE financial relations? It deepens cross-border financial flows post-CEPA and gives UAE investors access to India-focused investment options. 5. About the Kotak Mahindra Bank? It is one of India's largest private banks, renowned for retail and corporate banking, wealth management, and a growing international presence.
India Today
7 hours ago
- India Today
New health guidelines for high blood pressure: Don't ignore even mild high BP
High blood pressure, often called the 'silent killer,' is no longer just a Western health problem. In India, nearly 20 crore individuals are estimated to have hypertension, and the numbers are rising sharply in cities and smaller towns alike. It is now a leading cause of heart attacks, strokes, kidney failure, and even dementia.A new joint guideline from the American Heart Association (AHA) and the American College of Cardiology (ACC) is calling for earlier action through prevention, early treatment, and more personalised these guidelines are US-based, they carry lessons that are just as urgent for India. It says that high blood pressure should be treated earlier, not just with medicines, but also with healthy lifestyle changes. It stresses the need to carefully monitor blood pressure before, during and after pregnancy, and recommends using a new tool called the PREVENT risk calculator to check a person's chances of heart disease. Moderating alcohol intake is also one of the key ways to reduce high blood pressure, as per the new EARLY ACTION MATTERSHigh blood pressure doesn't always show symptoms until it has already caused serious damage. It is the pressure of the blood flow against the arteries is consistently can silently weaken blood vessels, strain the heart, and even harm the brain. New research highlighted in the guideline shows that hypertension can accelerate memory problems and increase the risk of dementia, a concern for India as life expectancy rises and cases of Alzheimer's disease grow.'High blood pressure is the most common and most modifiable risk factor for heart disease,' said Dr. Daniel W. Jones, chair of the guideline writing committee. Early diagnosis and treatment, he explained, not only prevent heart attacks and strokes but also protect long-term brain CHANGES AS THE FIRST TREATMENTFor most Indians, lifestyle is both the problem and the solution. Urban diets high in salt, processed foods, and fried snacks, combined with sedentary jobs and high stress, are fuelling the hypertension guideline reaffirms that healthy lifestyle habits such as cutting down on salt (a major challenge in Indian cooking and packaged foods), eating more fruits, vegetables and whole grains, exercising regularly, maintaining a healthy weight, and managing stress, remain the first line of alcohol, moderation is key. Stress management, whether through yoga, meditation, or simple breathing techniques, has particular resonance in India, where traditional practices can be powerful TOOL FOR PERSONALISED CAREThe new guideline recommends use of the PREVENT risk calculator, which helps doctors estimate an individual's 10- and 30-year risk of heart disease by considering factors like blood pressure, cholesterol, diabetes, and even socioeconomic not yet widely used in India, such tools highlight the importance of tailoring treatment to the person rather than following a one-size-fits-all India, where access to advanced tests is often limited, home blood pressure monitoring can also be a practical and cost-effective way to keep track of health between doctor WHEN NEEDEDWhile lifestyle remains central, medication is often necessary, especially when blood pressure remains high. The guideline suggests starting treatment earlier and, for those with very high readings (140/90 mm Hg or above), using two medicines together for faster used to begin medication mostly when people reached stage 2 hypertension (blood pressure of 140/90 mm Hg or higher). But the new guideline says treatment should start earlier, even at stage 1 hypertension (130–139/80–89 mm Hg), especially if a person has other risks like diabetes, kidney disease, or a family history of heart idea is that bringing blood pressure under control sooner, with lifestyle changes and medicines when needed, can prevent serious complications like heart attack, stroke, and dementia later in blood pressure: less than 120/80 mm Hg. This is where you want to blood pressure: between 120–129 (top number) and less than 80 (bottom number). This is a warning zone — not yet high blood pressure, but a signal to make lifestyle 1 hypertension: between 130–139 (top number) or 80–89 (bottom number). At this stage, doctors may recommend lifestyle changes and, if other health risks are present, starting 2 hypertension: 140/90 mm Hg or higher. This is more serious and usually requires medication along with lifestyle changes to bring numbers India, common medications like ACE inhibitors, ARBs, calcium channel blockers and diuretics are widely available and effective. For those with obesity and type 2 diabetes, both rising in the country, newer therapies such as GLP-1 drugs may offer added benefits in the ON WOMEN AND PREGNANCYThe guidelines also highlight high blood pressure in pregnancy, a serious concern in India where maternal health remains a challenge. Conditions like preeclampsia can threaten both mother and child and raise a woman's long-term risk of heart recommend close monitoring of blood pressure during and after pregnancy, timely treatment, and in some cases, low-dose aspirin to reduce risk. Postpartum follow-up is equally crucial, since blood pressure problems can persist or develop after deliveryAs Dr. Jones summed up, 'Prevention, early detection and management of high blood pressure are critical to long-term heart and brain health, which means longer, healthier lives.'advertisementFor India, this advice could not be more timely.- Ends
